gal 9 antibody Search Results


anti lgals9  (Proteintech)
93
Proteintech anti lgals9
Anti Lgals9, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/Galectin-9+Antibody/pm41437376-178-13-15
Average 93 stars, based on 1 article reviews
anti lgals9 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
rg9 35 7  (Miltenyi Biotec)
93
Miltenyi Biotec rg9 35 7
Rg9 35 7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/Galectin-9+Antibody%2C+anti-mouse/bio_rxiv__2023__08__03__551797-263-134-135
Average 93 stars, based on 1 article reviews
rg9 35 7 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
rea435  (Miltenyi Biotec)
92
Miltenyi Biotec rea435
Immunophenotyping panel for multiplexed tissue imaging of cancer.
Rea435, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/Galectin-9+Antibody%2C+anti-human%2C+REAfinity/pmc10985204-85-3-12
Average 92 stars, based on 1 article reviews
rea435 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
anti-gal-9 monoclonal antibody  (MBL Life science)
90
MBL Life science anti-gal-9 monoclonal antibody
Immunophenotyping panel for multiplexed tissue imaging of cancer.
Anti Gal 9 Monoclonal Antibody, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/gal+9+blocking+monoclonal+antibody+eca8/pmc03967371-150-2-6
Average 90 stars, based on 1 article reviews
anti-gal-9 monoclonal antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-gal-9 antibody clone sea309hu  (USCN Life)
90
USCN Life anti-gal-9 antibody clone sea309hu
Immunophenotyping panel for multiplexed tissue imaging of cancer.
Anti Gal 9 Antibody Clone Sea309hu, supplied by USCN Life, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/anti+gal+9+antibody+clone+sea309hu/us10899838-409-16-19
Average 90 stars, based on 1 article reviews
anti-gal-9 antibody clone sea309hu - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gal 9 pe  (Becton Dickinson)
90
Becton Dickinson gal 9 pe
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Gal 9 Pe, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/gal+9+pe+antibody/pmc08581324-80-39-42
Average 90 stars, based on 1 article reviews
gal 9 pe - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-gal-9 antibodies rg9-1  (GeneTex)
90
GeneTex anti-gal-9 antibodies rg9-1
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Anti Gal 9 Antibodies Rg9 1, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/anti+gal+9+antibodies+rg9+1/pmc09006662-147-4-14
Average 90 stars, based on 1 article reviews
anti-gal-9 antibodies rg9-1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-gal9 antibody 1g3  (BIOTEM Inc)
90
BIOTEM Inc anti-gal9 antibody 1g3
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Anti Gal9 Antibody 1g3, supplied by BIOTEM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/anti+gal9+antibody+1g3/pm38117000-136-15-20
Average 90 stars, based on 1 article reviews
anti-gal9 antibody 1g3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human igg fc antibody  (Bio-Techne corporation)
95
Bio-Techne corporation human igg fc antibody
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Human Igg Fc Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/Human+IgG+Fc+Antibody/bio-techne+corporation___g-102-c
Average 95 stars, based on 1 article reviews
human igg fc antibody - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
anti-gal9 antibodies  (PureTech Health PLC)
90
PureTech Health PLC anti-gal9 antibodies
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Anti Gal9 Antibodies, supplied by PureTech Health PLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/anti+gal9+antibodies/pm38287577-149-42-19
Average 90 stars, based on 1 article reviews
anti-gal9 antibodies - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gal-9 recombinant protein  (Abnova)
90
Abnova gal-9 recombinant protein
PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, <t>GAL‐9</t> and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes
Gal 9 Recombinant Protein, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gal+9+antibody/polyclonal+mouse+anti+human+gal+9+antibody/pm22469568-52-31-39
Average 90 stars, based on 1 article reviews
gal-9 recombinant protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
galectin 9 gal9 antibody  (Abbexa)
N/A
Polyclonal Antibody to Galectin 9 GAL9
   Buy from Supplier

Image Search Results


Immunophenotyping panel for multiplexed tissue imaging of cancer.

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Immunophenotyping panel for multiplexed tissue imaging of cancer.

Article Snippet: Galectin 9 , REA435 , 50 , 130-124-237 , PE (APC) , Miltenyi Biotec.

Techniques: Imaging

PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, GAL‐9 and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes

Journal: Journal of Cellular and Molecular Medicine

Article Title: Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential

doi: 10.1111/jcmm.16967

Figure Lengend Snippet: PRAME expression modulates immune checkpoint ligand expression and restores cancer cell killing ability to levels seen with PD‐L1 treatment. Multi‐parameter flow cytometry was conducted to assess the frequency of cancer cells expressing PD‐L1, CD86, GAL‐9 and VISTA immune checkpoint ligands after indirect co‐culture (72 h). A, Mean fold‐change in frequency of NC/OV cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of NC cells‐PBLs. B, Mean fold‐change in frequency of siCTRL/siPRAME cancer cells expressing respective immune checkpoint ligands ( n = 3 for each group). Fold‐change is relative to frequency of siCTRL cells ‐PBLs. C, Flow cytometry plots of single cell gated cancer cells in co‐culture with PBLs from one donor, representing 3 independent experiments. D, PD‐L1 expression analysis by flow cytometry after treatment with atezolizumab ( n = 2 for each group). E, Cell viability flow cytometry using 7‐AAD and QTracker labelling dye after treatment with atezolizumab ( n = 2 for each group). Non‐viable cancer cells were gated as positive for Qtracker and 7‐AAD staining. Combined data from 3 independent experiments, each performed with one donor (biological replicate), are shown in panels A, B and C. Panels D & E show combined data from 2 independent experiments, each performed with one donor (biological replicate). Bars indicate mean with standard error of mean (±SEM). Statistical analysis performed using paired Student's t ‐test (NC+PBLs vs OV+PBLs, OV‐PBLs vs OV+PBLs, siCTRL+PBLs vs siPRAME+PBLs, siCTRL‐PBLs vs siCTRL+PBLs). * p ≤ 0.05. NC, negative control; OV, PRAME overexpression, PBL, peripheral blood lymphocytes

Article Snippet: In parallel, we determined the expression of respective ligands: CD80 BV510 (740150, BD Biosciences), CD86 Alexa700 (564544, BD Biosciences), PD‐L1 PE‐Cy7 (558017, BD Biosciences), PD‐L2 BV786 (563843, BD Biosciences), VISTA BV421 (566750, BD Biosciences), MHC‐II BV650 (564231, BD Biosciences), GAL‐9 PE (565890, BD Biosciences) and PVR BUV395 (748272, BD Biosciences).

Techniques: Expressing, Flow Cytometry, Co-Culture Assay, Staining, Negative Control, Over Expression